Actively Recruiting
Study of Subcutaneous Ocrelizumab for Multiple Sclerosis Patients Switching From Approved Anti-CD20 Therapies
Led by Genentech, Inc. · Updated on 2026-10-30
100
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, patient outcomes, imaging biomarkers, and treatment satisfaction of ocrelizumab combined with recombinant human hyaluronidase when given as a subcutaneous injection in adults with relapsing or primary progressive multiple sclerosis who have switched from another approved anti-CD20 therapy. This phase 4 study focuses on participants who previously received ofatumumab, ublituximab-xiiy, or intravenous ocrelizumab treatments. Participants will receive two doses of ocrelizumab subcutaneously 920 milligrams on Day 1 and again at Week 24. The study observes this treatment given after switching from another anti-CD20 therapy, monitoring effects over time. The study uses a single group design without a placebo or comparison arm. During the study, participants will undergo brain MRI scans to measure changes in lesions at baseline, Week 24, and Week 48. Researchers will also assess adverse events, B-cell counts, and various treatment satisfaction questionnaires. The study includes assessments of disability and quality of life at multiple timepoints. Participation lasts up to 48 weeks, with safety and efficacy monitored throughout the study.
CONDITIONS
Brief Title
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Research Team
R
Reference Study ID Number: ML46740 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here